Literature DB >> 15659425

Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.

M L C Hagemans1, L P F Winkel, P A Van Doorn, W J C Hop, M C B Loonen, A J J Reuser, A T Van der Ploeg.   

Abstract

Late-onset Pompe's disease (acid maltase deficiency, glycogen storage disease type II) is a slowly progressive myopathy caused by deficiency of acid alpha-glucosidase. Current developments in enzyme replacement therapy require detailed knowledge of the kind and severity of symptoms and the natural course of the disease in the patient population. A detailed questionnaire covering the patients' medical history and current situation was developed and information was gathered from 54 Dutch patients. The mean age of the participants was 48.6 +/- 15.6 years. The first complaints started at a mean age of 28.1 +/- 14.3 years and were mostly related to mobility problems and limb-girdle weakness. Fifty-eight percent of the adult patients indicated the presence of mild muscular symptoms during childhood. Twenty-eight percent of the patients waited >5 years for the final diagnosis after the first visit to a physician for disease-related complaints. At the time of questionnaire completion, 48% of the study population used a wheelchair and 37% used artificial ventilation. Movements such as rising from an armchair, taking stairs or getting upright after bending over were difficult or impossible for more than two-thirds of the respondents. The age at onset, the rate of disease progression and the sequence of respiratory and skeletal muscle involvement varied substantially between patients. Seventy-six percent of the participants indicated being troubled by fatigue and 46% by pain. This survey has mapped the age at onset, presenting symptoms, heterogeneity in progression and range of disease severity in a large group of Dutch patients. We conclude that early manifestations in childhood require proper attention to prevent unnecessary delay of the diagnosis. The follow-up of patients with late-onset Pompe's disease should focus on respiratory and limb-girdle muscle function, the capacity to perform daily activities, and the presentation of fatigue and pain.

Entities:  

Mesh:

Year:  2005        PMID: 15659425     DOI: 10.1093/brain/awh384

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  99 in total

1.  Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.

Authors:  Stefania Zampieri; Emanuele Buratti; Silvia Dominissini; Anna Lisa Montalvo; Maria Gabriela Pittis; Bruno Bembi; Andrea Dardis
Journal:  Eur J Hum Genet       Date:  2010-12-22       Impact factor: 4.246

Review 2.  Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity.

Authors:  Toru Kubo; Hiroaki Kitaoka
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

3.  Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants.

Authors:  Paula Hernández-Arévalo; José D Santotoribio; Rocío Delarosa-Rodríguez; Antonio González-Meneses; Salvador García-Morillo; Pilar Jiménez-Arriscado; Juan M Guerrero; Hada C Macher
Journal:  Orphanet J Rare Dis       Date:  2021-05-21       Impact factor: 4.123

4.  Qualitative and quantitative skeletal muscle ultrasound in late-onset acid maltase deficiency.

Authors:  Craig M Zaidman; Elizabeth C Malkus; Catherine Siener; Julaine Florence; Alan Pestronk; Muhammad Al-Lozi
Journal:  Muscle Nerve       Date:  2011-07-13       Impact factor: 3.217

Review 5.  [Diagnosis and therapy of late onset Pompe disease].

Authors:  A Schüller; C Kornblum; M Deschauer; M Vorgerd; B Schrank; E Mengel; Z Lukacs; D Gläser; P Young; U Plöckinger; B Schoser
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

6.  In vivo bone architecture in pompe disease using high-resolution peripheral computed tomography.

Authors:  Aneal Khan; Zachary Weinstein; David A Hanley; Robin Casey; Colleen McNeil; Barbara Ramage; Steven Boyd
Journal:  JIMD Rep       Date:  2012-06-06

7.  Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.

Authors:  Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah
Journal:  Hum Gene Ther       Date:  2018-07-25       Impact factor: 5.695

8.  Fatigue: an important feature of late-onset Pompe disease.

Authors:  Marloes L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

Review 9.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

10.  Side-alternating vibration training improves muscle performance in a patient with late-onset pompe disease.

Authors:  Aneal Khan; Barbara Ramage; Ion Robu; Laura Benard
Journal:  Case Rep Med       Date:  2009-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.